Deletion of P2Y2 receptor reveals a role for lymphotoxin-α in fatty streak formation
- PMID: 27355755
- PMCID: PMC5453728
- DOI: 10.1016/j.vph.2016.06.001
Deletion of P2Y2 receptor reveals a role for lymphotoxin-α in fatty streak formation
Abstract
Background: Lymphotoxin alpha (LTα) is expressed in human atherosclerotic lesions and genetic variations in the LTα pathway have been linked to myocardial infarction. Activation of the P2Y2 nucleotide receptor (P2Y2R) regulates the production of LTα. in vitro. We aimed to uncover a potential pathway linking purinergic receptor to LTα-mediated inflammatory processes pivotal to the early stages of atherosclerosis in apolipoprotein E (ApoE(-)(/)(-)) deficient mice.
Methods and results: En face immunostaining revealed that P2Y2R and VCAM-1 are preferentially expressed in the atherosclerosis prone site of the mouse aortic sinus. Deletion of the P2Y2R gene suppresses VCAM-1 expression. Compared with ApoE(-)(/)(-) mice, ApoE(-)(/)(-) mice lacking the P2Y2R gene (ApoE(-)(/)(-)/P2Y2R(-)(/)(-)) did not develop fatty streak lesions when fed a standard chow diet for 15weeks. Systemic and CD4(+) T cell production of the pro-inflammatory cytokine lymphotoxin-alpha (LTα) were specifically inhibited in ApoE(-)(/)(-)/P2Y2R(-)(/)(-)mice. Anti-LTα preventive treatment was initiated in ApoE(-)(/)(-)mice with intraperitoneal administration of recombinant human tumor necrosis factor receptor 1 fusion protein (TNFR1-Fc) on 5 consecutive days before the disease onset. Remarkably, none of the TNFR1:Fc-treated ApoE(-)(/)(-)mice exhibited atherosclerotic lesions at any developmental stage.
Significance: ApoE(-)(/)(-) mice deficient in P2Y2R exhibit low endothelial cell VCAM-1 levels, decreased production of LTα and delayed onset of atherosclerosis. These data suggest that targeting this nucleotide receptor could be an effective therapeutic approach in atherosclerosis.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Therapeutic potential for P2Y2 receptor antagonism.Purinergic Signal. 2023 Jun;19(2):401-420. doi: 10.1007/s11302-022-09900-3. Epub 2022 Oct 11. Purinergic Signal. 2023. PMID: 36219327 Free PMC article. Review.
-
The P2Y2 nucleotide receptor is an inhibitor of vascular calcification.Atherosclerosis. 2017 Feb;257:38-46. doi: 10.1016/j.atherosclerosis.2016.12.014. Epub 2016 Dec 15. Atherosclerosis. 2017. PMID: 28038380 Free PMC article.
-
Endothelial Cell-Specific Deletion of P2Y2 Receptor Promotes Plaque Stability in Atherosclerosis-Susceptible ApoE-Null Mice.Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):75-83. doi: 10.1161/ATVBAHA.116.308561. Epub 2016 Nov 17. Arterioscler Thromb Vasc Biol. 2017. PMID: 27856454 Free PMC article.
-
IL-9 aggravates the development of atherosclerosis in ApoE-/- mice.Cardiovasc Res. 2015 Jun 1;106(3):453-64. doi: 10.1093/cvr/cvv110. Epub 2015 Mar 17. Cardiovasc Res. 2015. PMID: 25784693
-
The role of an experimental model of atherosclerosis: apoE-knockout mice in developing new drugs against atherogenesis.Curr Pharm Biotechnol. 2012 Oct;13(13):2435-9. Curr Pharm Biotechnol. 2012. PMID: 22280417 Review.
Cited by
-
How selective antagonists and genetic modification have helped characterise the expression and functions of vascular P2Y receptors.Purinergic Signal. 2024 May 13. doi: 10.1007/s11302-024-10016-z. Online ahead of print. Purinergic Signal. 2024. PMID: 38740733 Review.
-
P2Y Purinergic Receptors, Endothelial Dysfunction, and Cardiovascular Diseases.Int J Mol Sci. 2020 Sep 18;21(18):6855. doi: 10.3390/ijms21186855. Int J Mol Sci. 2020. PMID: 32962005 Free PMC article. Review.
-
P2 Receptors as Therapeutic Targets in the Salivary Gland: From Physiology to Dysfunction.Front Pharmacol. 2020 Mar 13;11:222. doi: 10.3389/fphar.2020.00222. eCollection 2020. Front Pharmacol. 2020. PMID: 32231563 Free PMC article. Review.
-
The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.Pharmacol Rev. 2019 Jul;71(3):345-382. doi: 10.1124/pr.117.014878. Pharmacol Rev. 2019. PMID: 31235653 Free PMC article. Review.
-
Association of G-protein coupled purinergic receptor P2Y2 with ischemic stroke in a Han Chinese population of North China.Neural Regen Res. 2019 Mar;14(3):506-512. doi: 10.4103/1673-5374.245472. Neural Regen Res. 2019. PMID: 30539820 Free PMC article.
References
-
- Jain M, Ridker P. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977–987. - PubMed
-
- Kam PC, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia. 2003;58:28–35. - PubMed
-
- Kunapuli SP, Ding Z, Dorsam RT, Kim S, Murugappan S, Quinton TM. ADP receptors-targets for developing antithrombotic agents. Curr Pharm Des. 2003;9:2303–2316. - PubMed
-
- Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001;86:222–232. - PubMed
-
- Gimbrone M. Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol. 1995;75:67–70. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous